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Chronic renal failureThe presence of impaired kidney function during heart failure and vice versa is a frequent occurrence. This situ-
ation is deﬁned “Cardio-renal Syndrome”.
In the Cardio-renal Syndrome (CRS) are included 5 different sub-syndromes deﬁned on the basis of the organ
primitively responsible: Acute Cardio-renal Syndrome (Type 1), Chronic Cardio-renal Syndrome (Type 2),
Acute Reno-cardiac Syndrome (Type 3), Chronic Renal-cardiac Syndrome (Type 4) and Secondary Cardio-renal
Syndrome (Type 5).
The physiopathologicmechanisms underlying CRS are still partially obscure, but, a key role seems to be played by
the renin-angiotensin-aldosterone axis.
Therapeutic strategies involved in CRS treatment include the use of diuretics, ACE inhibitors, Angiotensin Recep-
tor Blockers andβ-Blockers, emphasizing the role of a proper use ofmedication indicated for the treatment of car-
diac decompensation.
© 2014 Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1 . Introduction
The presence of a new-onset of renal failure, or the aggravation of a
pre-existing onewithin the ambit of an acute or chronic heart failure ex-
acerbation is frequently found in daily cardiologic clinical practice. It
also frequently occurs as a contemporary and progressive cardiac in-
volvement in the development of cadres of renal failure [1].
Existing relationships between the two diseases had not been fully
elucidated for a long time, although it soon became evident that the si-
multaneous involvement of the two apparatuses conditioned the prog-
nosis in a pejorative sense [2].
Frequent detailed evidence in literature found a deﬁnite classiﬁca-
tion to this effect in the speciﬁc ‘consensus’ conference held in Venice
in 2008 [3], which enabled the deﬁnition of clinical pictures and physio-
pathological shared areas within the ambit of the Cardio-renal Syn-
drome (CRS).
2. Classiﬁcation of the CRS
General deﬁnition: The Cardio-renal Syndrome is a physiopatholog-
ical disorder of the heart and kidneys inwhich the acute or chronic dys-
function of one organ induces acute or chronic dysfunction in the other
[2,3].
In the sense deﬁned above 5 subtypes can be identiﬁed:
– Type 1 Acute Cardio-renal Syndrome: acute worsening of cardiac
function that determines renal dysfunction;
– Type 2 Chronic Cardio-renal Syndrome: chronic abnormalities in car-
diac function that determines renal dysfunction;is an open access article under the C– Type 3 Acute Reno-cardiac Syndrome: acute worsening of renal func-
tion that determines cardiac dysfunction;
– Type 4 Chronic Reno-cardiac Syndrome: chronic abnormalities of
renal function that determine a cardiac dysfunction;
– Type 5 Secondary Cardio-Renal Syndrome: simultaneous cardiac and
renal dysfunction caused by an acute systemic condition.
3. Acute Cardio-renal Syndrome (CRS Type 1)
This condition occurs when an acute deterioration of cardiac func-
tion determines an “Acute kidney injury (AKI)” and/or Acute renal fail-
ure (ARF).
The spectrum of acute cardiac conditions that may contribute to a
worsening of renal function in the sense of the development of
Cardio-renal Acute Syndrome (CRS Type 1) includes:
– acutely decompensated heart failure (ADHF),
– acute coronary syndrome (ACS),
– cardiogenic shock, and
– low-ﬂow syndrome following cardiac surgery.
Also attributable to this type of renal impairment is the nephrotoxic
effect due to contrast medium, widely used in diagnostic tests indicated
in acute cardiac conditions that give rise to CRS Type 1.
Acute impairment of renal function, as evidenced by an increase
greater than 0.3 mg/dl of baseline serum creatinine, occurring in aC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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or acute coronary syndrome [2].
The development of a CRS Type 1 causes a signiﬁcant deterioration
in morbidity and mortality as well as prolonged hospitalization [4].
4. Chronic Cardio-renal Syndrome (CRS Type 2)
It is a very common situation, which occurs when chronic renal fail-
ure develops during cardiac impairment (CRF). Approximately 63% of
patients with chronic congestive heart failure presents a picture of
chronic renal failure (Stages 3–5), with values of glomerular ﬁltrate
(GF) inferior to 60 ml/min/m2 [2].
The deﬁnition of “chronic cardiac impairment” includesmany differ-
ent heart conditions:
– chronic heart failure,
– atrial ﬁbrillation,
– congenital cyanotic heart disease,
– constrictive pericarditis, and
– chronic ischemic heart disease.
Since the coexistence of chronic cardiac impairment in chronic kid-
ney disease is not uncommon, it can be difﬁcult to deﬁne which condi-
tion is pre-existing and, in this sense, an accurate anamnestic
reconstruction is extremely valuable.
In this subtype (CRS Type 2), the coexistence of two pathological
conditions, renal and cardiac, also worsens prognosis, both in terms of
increased morbidity and in the sense of an increased mortality risk
[5–7], therefore renal failure can be considered a negative prognostic
factor in the independent assessment of the evolution of a framework
of heart failure.
5. Acute Reno-cardiac Syndrome (CRS Type 3)
CRS Type 3 is identiﬁable in the situation where an acute deteriora-
tion of renal function (ARF) results in damage and/or acute cardiac
dysfunction.
The boundaries of this condition are still partially undeﬁned, since it
is only possible to rely on occasional and unsystematic reports. Typical
clinical conditions consist in:
– drug-induced acute renal disease,
– acute renal failure after major surgery (cardiac and non),
– acute nephritic syndromes, and
– Rhabdomyolysis.
This type of CRS also refers to acute renal failure from medium con-
trast (CI-AKI), especially if not determined by diagnostic tests aimed at
evaluating a preexistent heart disease, which otherwise would identify
a Type 1 CRS. These conditions of AKI are frequently accompanied by the
development of acute coronary syndrome, arrhythmias, acute decom-
pensation and EPA [3].
6. Chronic Reno-cardiac Syndrome (CRS Type 4)
Type 4 CRS consists of the condition inwhich primitive chronic renal
failure (CRF) contributes to the deterioration of cardiac function (e.g.
cardiac remodeling, left ventricular diastolic dysfunction, left ventricu-
lar hypertrophy) with an increased risk of acute cardiovascular events
(myocardial infarction, stroke, acute heart failure).
The presence of chronic renal failure in this group of patients deter-
mines a mortality rate 10–20 times higher than in a comparable popu-
lation by age and sex, but without IRC [3,4].
Observational and population studies have largely documented a
rising trend in morbidity and mortality from cardiovascular diseasewith the passage to worsening stages of renal dysfunction (from stage
1 to stage 3) [8–12].
An inverse relationship emerges between renal function and nega-
tive cardiovascular outcome for high-risk cohorts, the creatinine clear-
ance is a short-term predictor of poor outcome (cardiovascular death
or myocardial infarction) [8].
This negative correlation, if basically pre-existent, could be further
compounded by a kind of fear, or “therapeutic nihilism” attitude to-
wards personswith renal insufﬁciency, in which less attention is devot-
ed tomodifying traditional cardiovascular risk factors [13,14], as a result
of a less aggressive therapeutic approach for fear of a further deteriora-
tion of renal function associated with the use of drugs [8,15,16].
7. Secondary Cardio-renal Syndrome (CRS Type 5)
Type 5 CRS is characterized by an acute or chronic systemic disease
that causes simultaneous cardiac and renal dysfunction.
Examples of this can be found in sepsis, SLE, amyloidosis, diabetes
mellitus, and sarcoidosis. The co-existence of aggravating conditions,
such as diabetes and/or hypertension, may increase the severity of the
impairment of the two organs.
The physiopathological characteristics of condition have not yet
been well deﬁned, but it has its own current epidemiological logic.
8. Physiopathology of CRS
Physiopathological mechanisms supporting the simultaneous in-
volvement of cardiovascular and renal functions in the manifestation
of CRS are complex and have not yet been fully elucidated. In heart fail-
ure, the impairment of systolic and/or diastolic blood pressure leads to a
series of adjustments that are conﬁgured in the decrease of cardiac out-
put, stroke volume, and ﬁnally in reduced circulating volume [17]
(Fig. 1).
The decrease in arterial circulating blood volume is taken up by arte-
rial baroreceptors and causes neurohormonal activation that produces
compensatory mechanisms aimed at correcting the state of relative hy-
povolemia and restoring proper tissue perfusion. In this sense, activa-
tion of the reninaangiotensina-aldosterone system (RAAS), the
sympathetic nervous system (SNS), endothelin system and arginine–
vasopressin causes water retention, mediated by sodium–retentive va-
soconstriction, and counterbalanced by the activation of vasodilatory
natriuretic hormone (natriuretic peptide) systems and cytokines (pros-
taglandins, bradykinin, NO) [18,19].
Under normal conditions, these mechanisms act unanimously in
maintaining vascular tone and normalize cardiac output and tissue
perfusion.
However, in terms of heart failure, the samemechanisms act by per-
petuating vicious circles that waver, ﬁnally, in a state of chronic renal
hypoxia, inﬂammation and oxidative stress which alone can alter cardi-
ac and renal structure and function [20].
The activation of SRAA determines renal hypoxia, vasoconstriction,
intraglomerular hypertension, glomerulosclerosis, tubulointerstitial ﬁ-
brosis and proteinuria [21], and proteinuria [21,22]. Similarly the activa-
tion of the SNS involves proliferation of smooth muscle cells and
adventitial ﬁbroblasts in the intrarenal vascular walls [23].
An attempt to attribute the responsibility of renal impairment to ini-
tial hemodynamic components, or modify the therapy in the course of
acute heart failure has produced controversial and ultimately inade-
quate explanations, both because responsibility for the changes in cardi-
ac output has not been identiﬁed, inasmuch as kidneys are able to
tolerate decreases in cardiac index up to 1.5 l/min/m2 [24,25], and also
because renal failure can occur under conditions of both low as well as
preserved tissue perfusion [20,25]. The only hemodynamic variable in-
volved is the right atrial pressure (or central venous) [26].
Transrenal perfusion pressure is calculated from the mean arterial
pressure minus the central venous pressure: therefore even a modest
Fig 1.
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tails a clear impairment of renal perfusion pressure [27,28]: this condi-
tion can aggravate pre-existing renal impairment or determine acute
impairment of renal function which, in addition to neuro-hormonal
mechanisms triggered by the failure, aggravates conditions for compen-
sation of cardiac and renal function in a vicious cycle.
To the above listed conditionsmust be added the direct effect of ure-
mia in determining Uremic Heart Disease, a peculiar cardiomyopathy,
which adds to and somewhat overlaps already compromised pre-
existing cardiac conditions [31].Table 1
Da: ESCGuidelines for the diagnosis and treatment of acute and chronic heart failure 2008
[30].
Terapia dello scompenso: raccomandazioni di Classe I
ACE Inibitori Tutti i pazienti Classe I
Livello A








Sintomi severi in ACEI Classe I
Livello A




To date, no one has identiﬁed and deﬁned a speciﬁc therapeutic di-
rection in the treatment of the Cardio-renal Syndrome.
Current evidence indicates that an optimal treatment of acute and
chronic SCC, with an appropriate use of drugs proven to be effective
(ACE-I, Angiotensin receptor inhibitors, beta-blockers, diuretics, …) is
the best therapy possible [30] (Tables 1–2).
In practical terms, a) the introduction of therapy with an ACEI or ARB,
must not cause alarm because of an expected increase of up to 33% in the
initial values of serum creatinine. Further and more substantial increases
should suggest carefulmonitoring of the state of the patient's hydration,
an eventual concomitant use of drugs interfering with the SRAA
(NSAIDs), as well as recommending a thorough study of the renal
vessels.
b)When using diuretic therapy in the presence of CRSwith advanced
renal impairment (FG _30 ml/min/m2), the class of drugs of choice con-
sists of loop diuretics (furosemide, torasemide) whose dosage should
be gradually increased to attain the expected result, with a careful
check of the water balance between the introduction and diuresis, inorder to prevent the onset of a condition of hyponatremia, aggravating
the condition of failure.
Untrainﬁltation techniques, although yet to be clearly deﬁned both for
distinct and niche populations, are not of secondary importance. Finally,
the most crucial health facilities consist of constant suspicion and care-
ful research of signs that lead to timely diagnosing renal impairment in
all conditions of acute or chronic heart failure and/or ischemic heart
disease.
Finally, a routine determination of FG value (with the formulas
MDRD or Cockcroft–Gault is sufﬁcient [29]. Convenient calculators are
easily available online: e.g. http://www.mdcalc.com) to provide en-
lightening information. To integrate a possible error of GFR estimate cal-
culated, under conditions of severe ARF, the assessment of the rate of
progression (slope) of creatinine values is revealing.
Table 2
Da: ESCGuidelines for the diagnosis and treatment of acute and chronic heart failure 2008
[30].
Terapia dello scompenso: dosaggio dei famaci
Dose dl attaco (mg) Dose target (mg)
ACEI
captopril 6.25 t.i.d 50–100 t.i.d.
enalapril 2.5 b.i.d 10–20 b.i.d
lisinopril 2.5–5.0 o.d 20–35 o.d.
ramipril 2.5 o.d. 5 b.i.d
trandolapril 0.5 o.d. 4 o.d.
ARB
candesartan 4–8 o.d. 32 o.d.
valsartan 40 b.i.d. 160 b.i.d.
AntagonIstI Aldosterone
eplerenone 25 o.d. 50 o.d.
spironolattone 25 o.d. 25–50 o.d.
Beta-BloccantI
bisoprololo 1.25 o.d. 10 o.d.
carvedilolo 3.125 b.i.d. 25–50 b.i.d.
metoprololo 12.5–25 o.d. 200 o.d.
nebivololo 1.25 o.d. 10 o.d.
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